Sonavex
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $335k | Grant | |
N/A | $225k | Grant | |
$150k | Grant | ||
$320k | Seed | ||
N/A | $2.2m | Early VC | |
$3.5m | Series A | ||
N/A | Grant | ||
$1.0m | Series A | ||
$3.0m | Grant | ||
N/A | $1.8m | Early VC | |
* | $1.7m | Grant | |
Total Funding | €12.9m |
Related Content
Recent News about Sonavex
EditSonavex is a medical technology company specializing in ultrasound-based vascular monitoring solutions. The company operates in the healthcare market, primarily serving hospitals, clinics, and surgical centers. Sonavex's core products, EchoMark and EchoSure, are designed to simplify and enhance the process of blood flow monitoring. EchoMark is the first-ever ultrasound marker for blood vessels, while EchoSure automatically detects flow loss using ultrasound technology. These innovations allow non-expert users to perform real-time, definitive, visual, and quantitative blood flow monitoring, which traditionally required expert sonographers.
Sonavex's business model revolves around the sale and limited release of its commercial products, supported by recent financing. The company generates revenue through the direct sale of its devices to healthcare providers and potentially through partnerships and collaborations within the medical field.
Keywords: ultrasound, vascular monitoring, EchoMark, EchoSure, blood flow, non-expert users, healthcare, medical technology, real-time analysis, FDA cleared.